Destiny Pharma plc (GB:DEST) has released an update.
Destiny Pharma plc, a clinical-stage biotech company, has announced the issuance of 258,748 new ordinary shares following a former director’s option exercise, with trading on the London Stock Exchange set to begin on 25 June 2024. This event will bring the total number of shares in issue to 95,770,611, which is pertinent information for shareholders monitoring changes in company share capital. The company is known for its focus on developing novel treatments for life-threatening infections, including a biotherapeutic for C. difficile and a nasal gel aimed at preventing post-surgical infections.
For further insights into GB:DEST stock, check out TipRanks’ Stock Analysis page.
